methyl (E)-4-(3-tert-butoxy-3-oxoprop-1-enyl)-3,5-dimethylbenzoate | 910132-85-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl (E)-4-(3-tert-butoxy-3-oxoprop-1-enyl)-3,5-dimethylbenzoate
• 英文别名: methyl (E)-4-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-3,5-dimethylbenzoate；4-(2-tert-butoxycarbonyl-vinyl)-3,5-dimethyl-benzoic acid methyl ester；methyl 3,5-dimethyl-4-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]benzoate
• CAS: 910132-85-3
• 化学式: C₁₇H₂₂O₄
• 分子量: 290.359
• InChiKey: FBIYWOJCTBGILQ-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (E)-4-(3-tert-butoxy-3-oxoprop-1-enyl)-3,5-dimethylbenzoate 在 palladium on activated charcoal N-甲基吗啉 、 氨 、 氢气 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 三氟乙酸 为溶剂， 20.0~60.0 ℃ 、413.68 kPa 条件下， 反应 75.5h， 生成 (4S,7S,13S)-13-[3-(4-carbamoyl-2,6-dimethylphenyl)propanoylamino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
  参考文献：
  名称：

  Replacement of the N-terminal Tyrosine Residue in Opioid Peptides with 3-(2,6-Dimethyl-4-carbamoylphenyl)propanoic Acid (Dcp) Results in Novel Opioid Antagonists

  摘要：

  3-(2,6-Dimethyl-4-carbamoylphenyl) propanoic acid (Dcp), a 2',6'-dimethyltyrosine analogue containing a carbamoyl group in place of the hydroxyl function and lacking the amino group, was synthesized. The replacement of Tyr(1) in an enkephalin analogue and in dynorphin A(1-11)-NH2 with Dcp resulted in the first opioid peptide-derived antagonists that do not contain a phenolic hydroxyl group at the 1-position residue. The cyclic peptide Dcp-c[D-Cys-Gly-Phe(pNO(2))-D-Cys] NH2 represents a novel, potent mu opioid antagonist.

  DOI：

  10.1021/jm060369k
• 作为产物：
  描述：

  2,6-二甲基苯酚 在 三乙胺 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 potassium iodate 、 copper(l) iodide 、 正丁基锂 、 硫酸 、 三乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.16h， 生成 methyl (E)-4-(3-tert-butoxy-3-oxoprop-1-enyl)-3,5-dimethylbenzoate
  参考文献：
  名称：

  Replacement of the N-terminal Tyrosine Residue in Opioid Peptides with 3-(2,6-Dimethyl-4-carbamoylphenyl)propanoic Acid (Dcp) Results in Novel Opioid Antagonists

  摘要：

  3-(2,6-Dimethyl-4-carbamoylphenyl) propanoic acid (Dcp), a 2',6'-dimethyltyrosine analogue containing a carbamoyl group in place of the hydroxyl function and lacking the amino group, was synthesized. The replacement of Tyr(1) in an enkephalin analogue and in dynorphin A(1-11)-NH2 with Dcp resulted in the first opioid peptide-derived antagonists that do not contain a phenolic hydroxyl group at the 1-position residue. The cyclic peptide Dcp-c[D-Cys-Gly-Phe(pNO(2))-D-Cys] NH2 represents a novel, potent mu opioid antagonist.

  DOI：

  10.1021/jm060369k

文献信息

• [EN] PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS<br/>[FR] DÉRIVÉS DE PYRIDIN-2-YLE UTILISÉS COMME AGENTS IMMUNOMODULATEURS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009109872A1

  公开（公告）日：2009-09-11

  The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  这项发明涉及公式（I）的吡啶衍生物，其中A、R1、R2、R3、R4、R5、R6和R7如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
  申请人：Bolli Martin

  公开号：US20100087417A1

  公开（公告）日：2010-04-08

  The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及新型氨基吡啶衍生物，其制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• Modular Dual-Tasked C–H Methylation via the Catellani Strategy
  作者：Qianwen Gao、Yong Shang、Fuzhen Song、Jinxiang Ye、Ze-Shui Liu、Lisha Li、Hong-Gang Cheng、Qianghui Zhou

  DOI：10.1021/jacs.9b07857

  日期：2019.10.9

  We report a dual-tasked methylation based on cooperative palladium/norbornene catalysis. Readily available (hetero)aryl halides (39 iodides and 4 bromides) and inexpensive MeOTs or trimethylphosphate are utilized as the substrates and meth-ylating reagent, respectively. Six types of ipso terminations can modularly couple with this ortho C-H methylation to consti-tute a versatile methylation toolbox

  我们报告了基于协同钯/降冰片烯催化的双任务甲基化。容易获得的（杂）芳基卤化物（39 个碘化物和 4 个溴化物）和廉价的 MeOT 或磷酸三甲酯分别用作底物和甲基化试剂。六种类型的 ipso 末端可以与这种邻位 CH 甲基化模块化耦合，构成一个通用的甲基化工具箱，用于制备多样化的甲基化芳烃。该工具箱具有廉价的甲基来源、出色的官能团耐受性、简单的反应程序和可扩展性。重要的是，通过切换到相应的试剂 CD3OT 或 13CH3OT，它可以顺利地扩展到同位素标记的甲基化。此外，该工具箱可用于具有完全立体保留的生物相关底物的后期修饰。
• [EN] PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009109906A1

  公开（公告）日：2009-09-11

  The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  这项发明涉及吡啶化合物，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS
  申请人：Boli Martin

  公开号：US20100240717A1

  公开（公告）日：2010-09-23

  The invention relates to thiophene derivatives of formula (I)/their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents wherein: A represents *—CO—CH═CH—, *—CO—CH 2 CH 2 —, *—CO—CH 2 —NH—, wherein the sterisks indicate the bond that is linked to the thiophene group of Formula (I), and R1-R3 are as defined in the claims.

  本发明涉及公式（I）的噻吩衍生物/它们的制备及其作为药物活性化合物的用途。所述化合物特别作为免疫抑制剂，其中：A代表*—CO—CH═CH—、*—CO— —、*—CO—CH2—NH—，其中星号表示与公式（I）的噻吩基团相连的键，R1-R3如权利要求所定义。